Vir Biotechnology Stock Performance
| VIR Stock | USD 5.41 0.08 1.46% |
The entity has a beta of 1.62, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vir Biotechnology will likely underperform. At this point, Vir Biotechnology has a negative expected return of -0.0419%. Please make sure to validate Vir Biotechnology's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to decide if Vir Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Vir Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable forward indicators, Vir Biotechnology is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
One Day Return (1.46) | Five Day Return 1.69 | Year To Date Return (25.58) | Ten Year Return (61.41) | All Time Return (61.41) |
1 | Disposition of 1562 shares by Brent Sabatini of Vir Biotechnology at 9.4534 subject to Rule 16b-3 | 04/28/2025 |
2 | Vir Biotechnology Unveils Promising Hepatitis B Treatment Data VIR Stock News | 05/09/2025 |
3 | Vir Biotechnology, Inc. Shares Sold by Voloridge Investment Management LLC | 05/27/2025 |
4 | Acquisition by Bischofberger Norbert W of 16000 shares of Vir Biotechnology at 4.94 subject to Rule 16b-3 | 05/30/2025 |
5 | Disposition of 3200 shares by Napolitano Janet of Vir Biotechnology at 5.0465 subject to Rule 16b-3 | 06/02/2025 |
6 | Positive Outlook on Vir Biotechnologys VIR-5500 Amid Competitive mCRPC Market - TipRanks | 06/04/2025 |
7 | Acquisition by Bischofberger Norbert W of 10667 shares of Vir Biotechnology subject to Rule 16b-3 | 06/06/2025 |
8 | Disposition of 14027 shares by More Robert J of Vir Biotechnology subject to Rule 16b-3 | 06/09/2025 |
9 | Is Vir Biotechnology In A Good Position To Deliver On Growth Plans | 06/25/2025 |
10 | Disposition of 22000 shares by Sato Vicki L of Vir Biotechnology at 5.1003 subject to Rule 16b-3 | 07/01/2025 |
11 | Insider Sell Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc | 07/03/2025 |
12 | Vir Biotechnology Soars 11.9 percent Is Further Upside Left in the Stock - Yahoo Finance | 07/10/2025 |
13 | Raymond James Starts Coverage on Vir Biotechnology with Positive Outlook VIR Stock News | 07/11/2025 |
14 | Disposition of 6796 shares by Eisner Mark of Vir Biotechnology at 5.4682 subject to Rule 16b-3 | 07/15/2025 |
15 | Disposition of 3586 shares by Eisner Mark of Vir Biotechnology at 5.4738 subject to Rule 16b-3 | 07/17/2025 |
| Begin Period Cash Flow | 261.3 M | |
| Total Cashflows From Investing Activities | 499.4 M |
Vir Biotechnology Relative Risk vs. Return Landscape
If you would invest 580.00 in Vir Biotechnology on April 22, 2025 and sell it today you would lose (39.00) from holding Vir Biotechnology or give up 6.72% of portfolio value over 90 days. Vir Biotechnology is generating negative expected returns assuming volatility of 3.7825% on return distribution over 90 days investment horizon. In other words, 33% of stocks are less volatile than Vir, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Vir Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vir Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vir Biotechnology, and traders can use it to determine the average amount a Vir Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0111
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VIR |
Estimated Market Risk
| 3.78 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vir Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vir Biotechnology by adding Vir Biotechnology to a well-diversified portfolio.
Vir Biotechnology Fundamentals Growth
Vir Stock prices reflect investors' perceptions of the future prospects and financial health of Vir Biotechnology, and Vir Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vir Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (45.69) % | ||||
| Current Valuation | 42.3 M | ||||
| Shares Outstanding | 138.24 M | ||||
| Price To Earning | 3.16 X | ||||
| Price To Book | 0.72 X | ||||
| Price To Sales | 35.85 X | ||||
| Revenue | 74.2 M | ||||
| Gross Profit | (476.86 M) | ||||
| EBITDA | (537.61 M) | ||||
| Net Income | (521.96 M) | ||||
| Cash And Equivalents | 2.2 B | ||||
| Cash Per Share | 16.55 X | ||||
| Total Debt | 97.89 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 4.79 X | ||||
| Book Value Per Share | 7.56 X | ||||
| Cash Flow From Operations | (446.35 M) | ||||
| Earnings Per Share | (4.23) X | ||||
| Market Capitalization | 747.87 M | ||||
| Total Asset | 1.4 B | ||||
| Retained Earnings | (759.78 M) | ||||
| Working Capital | 922.8 M | ||||
About Vir Biotechnology Performance
Assessing Vir Biotechnology's fundamental ratios provides investors with valuable insights into Vir Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vir Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 42.86 | 38.10 | |
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.46) | (0.44) | |
| Return On Assets | (0.37) | (0.35) | |
| Return On Equity | (0.45) | (0.43) |
Things to note about Vir Biotechnology performance evaluation
Checking the ongoing alerts about Vir Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vir Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vir Biotechnology generated a negative expected return over the last 90 days | |
| Vir Biotechnology has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 74.2 M. Reported Net Loss for the year was (521.96 M) with loss before taxes, overhead, and interest of (476.86 M). | |
| Vir Biotechnology has about 2.2 B in cash with (446.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.55, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 79.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Iovance Biotherapeutics Appoints New CFO Corleen Roche IOVA Stock News |
- Analyzing Vir Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vir Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Vir Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vir Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vir Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vir Biotechnology's stock. These opinions can provide insight into Vir Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.